TamirBio is a clinical stage antiviral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions. TamirBio first target is the human papilloma virus (HPV), the worldwide leading cause of genital warts. TamirBio is also targeting the acute treatment of the Ebola virus (EBV).

from http://tamirbio.com/about/

Publications show all

Tamir Biotechnology has published 3 articles.

Patents show all

11Applications3Issued

Clinical Trials show all

1Phase 1/Phase 21Phase 2

SEC Filings show all

8-K7910-Q4810-K16D7S-11